2-(4-hydroxy-phenyl)-7-methyl-3-p-tolyl-1H-inden-5-ol | 1019984-00-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-(4-hydroxy-phenyl)-7-methyl-3-p-tolyl-1H-inden-5-ol
• 英文别名: 2-(4-hydroxyphenyl)-7-methyl-3-(4-methylphenyl)-1H-inden-5-ol
• CAS: 1019984-00-9
• 化学式: C₂₃H₂₀O₂
• 分子量: 328.411
• InChiKey: JXIVHLNOIMEHHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-methoxy-2-(4-methoxyphenyl)-7-methyl-3-(4-methylphenyl)-1H-indene 在 三溴化硼 、 水 、 碳酸氢钠 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-(4-hydroxy-phenyl)-7-methyl-3-p-tolyl-1H-inden-5-ol
  参考文献：
  名称：

  WO2008/43567

  摘要：

  公开号：

文献信息

• 2-Phenyl indene derivatives useful as estrogen receptor ligands
  申请人：Jernstedt Henrik

  公开号：US20090326018A1

  公开（公告）日：2009-12-31

  The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. Formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are as defined in the specification, and wherein either the bond between the C1 and C2 carbon atoms is a double bond or the bond between the C2 and C3 carbon atoms is a double bond, R 2 being absent when the bond between the C1 and C2 carbon atoms is a double bond.

  本发明提供了化合物(I)或其药学上可接受的酯、酰胺、溶剂合物或盐，包括这种酯或酰胺的盐，以及这种酯、酰胺或盐的溶剂合物。本发明还提供了在与雌激素受体活性相关的疾病或紊乱的情况下使用这些化合物进行治疗或预防的方法。其中，化合物(I)的R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和R12如规范中所定义，在C1和C2碳原子之间的键是双键或C2和C3碳原子之间的键是双键时，R2不存在。
• [EN] 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE 2-PHÉNYL INDÈNE UTILISABLES EN TANT QUE LIGANDS DU RÉCEPTEUR DES OETROGÈNES
  申请人：KAROBIO AB

  公开号：WO2008043567A1

  公开（公告）日：2008-04-17

  [EN] The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. Formula (I), wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ and R¹² are as defined in the specification, and wherein either the bond between the C1and C2 carbon atoms is a double bond or the bond between the C2 and C3 carbon atoms is a double bond, R² being absent when the bond between the C1 and C2 carbon atoms is a double bond.
  [FR] La présente invention concerne un composé de formule (I) ou un ester, un amide, un solvate ou son sel pharmaceutiquement acceptables, y compris un sel d'un tel ester ou amide et un solvate d'un tel ester, amide ou sel. L'invention concerne également l'utilisation de tels composés pour le traitement ou la prophylaxie d'un état associé à une maladie ou à une affection liée à une activité de récepteur des oetrogènes. (I) dans laquelle R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ et R¹² sont tels que définis dans la description et dans laquelle soit la liaison entre les atomes de carbone C₁ et C₂ est une double liaison, soit la liaison entre les atomes de carbone C₂ et C₃ est une double liaison, R² étant absent lorsque la liaison entre les atomes de carbone C₁ et C₂ est une double liaison.
• [EN] ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS<br/>[FR] AGONISTES DU RÉCEPTEUR BÊTA DES OESTROGÈNES (ERβ) POUR LE TRAITEMENT D'ÉTATS FIBROTIQUES
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2020160225A1

  公开（公告）日：2020-08-06

  Disclosed are method of treating fibrotic conditions using estrogen receptor β (ERβ) agonists.
• [EN] METHODS OF MODULATING T-CELL ACTIVATION USING ESTROGEN RECEPTOR BETA (ERΒ) AGONISTS<br/>[FR] MÉTHODES DE MODULATION DE L'ACTIVATION DES LYMPHOCYTES T À L'AIDE D'AGONISTES DU RÉCEPTEUR BÊTA DES ŒSTROGÈNES (ERΒ)
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2021183760A1

  公开（公告）日：2021-09-16

  Disclosed are method of modulating immune response in a subject using ERβ agonists. The ERβ agonists can selectively inhibit the activation and/or proliferation of T-cells, reducing circulating T-cell levels in a subject without significantly affecting circulating levels of neutrophils, monocytes, or B-cells. As a result, the ERβ agonists can be used in therapeutic and/or prophylactic applications, including to treat or prevent chronic heart failure (CHF) in a subject post-myocardial infarction (MI) and to treat or prevent graft-versus-host disease (GVHD), multiple sclerosis (MS), and/or experimental autoimmune encephalomyelitis (EAE) in a subject.
• WO2008/43567
  申请人：——

  公开号：——

  公开（公告）日：——